Boldly going where few pharma companies have gone before, Bristol Myers Squibb has hitched a ride with SpaceX to chart the next chapter of its biomanufacturing journey among the stars.

After a round of layoffs in late January cut Amgen’s workforce by 300, the company has put another 450 jobs on the chopping block.

The job cuts represent less than 2% of the company’s total workforce of over 25,000, according to a statement that Amgen sent to Fierce Pharma. “We made these choices to realign our expense base in the face of intensifying pressure on drug prices and high levels of inflation so we can continue to deliver value for our patients, staff and shareholders,” the statement continued.